B-type natriuretic peptide: Beyond diagnostic applications

The Kidney in Heart Failure

Volumn 9781461436942, Issue , 2012, Pages 67-77

  Hanson, Ivan D ^a   McCullough, Peter A ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949179081     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3694-2_6     Document Type: Chapter

References (46)

1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356(9224):147-52.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
3. Chen WC, Tran KD, Maisel AS. Biomarkers in heart failure. Heart. 2010;96(4):314-20.
4. Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158(2):360-8.
5. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 1993;88(2):372-80.
6. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-68.
7. Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-Type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem. 1997;272(33):20545-54.
8. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-Type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451(2): 160-6.
9. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3 , 5 -cyclic monophosphate activating actions of various molecular forms of human B-Type natriuretic peptide. Hypertension. 2007;49(5):1114-9.
10. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-Type natriuretic peptide. J Am Coll Cardiol. 2007;49(10):1071-8.
11. Mair J. Biochemistry of B-Type natriuretic peptide-where are we now?. Clin Chem Lab Med. 2008;46(11):1507-14.
12. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76(1):91-6.
13. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4(1):37-44.
14. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-Type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83-8.
15. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996;271((2 Pt 2)): R373-80.
16. Ng LL, Geeranavar S, Jennings SC, Loke I, O'Brien RJ. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106(2):129-33.
17. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond). 1998;95(5):547-55.
18. Goetze JP, Jensen G, Moller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-Terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest. 2006;36(1):8-15.
19. Weber M, Hamm C. Role of B-Type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-9.
20. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7.
21. Das SR, Abdullah SM, Leonard D, et al. Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol. 2008;102(10): 1394-8.
22. McCullough PA, Duc P, Omland T, et al. B-Type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-9.
23. Januzzi Jr. JL, Camargo CA, Anwaruddin S, et al. The N-Terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-54.
24. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-Terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91-7.
25. Ishizaka Y, Yamamoto Y, Fukunaga T, et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994;24(3):461-72.
26. Akiba T, Tachibana K, Togashi K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44 Suppl 1:S61-4.
27. Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59(4):1559-66.
28. Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fi stula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis. 2002;40(5):974-82.
29. Sa fl ey DM, Awad A, Sullivan RA, et al. Changes in B-Type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. Adv Chronic Kidney Dis. 2005;12(1):117-24.
30. Flemmer M, Rajab H, Mathena T, et al. Blood B-Type natriuretic peptide and dialysis: present assessment and future analyses. South Med J. 2008;101(11):1094-100.
31. Linssen GC, Damman K, Hillege HL, Navis G, van Veldhuisen DJ, Voors AA. Urinary N-Terminal prohormone brain natriuretic peptide excretion in patients with chronic heart failure. Circulation. 2009;120(1):35-41.
32. Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-Terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol. 2008;102(4):469-74.
33. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-Term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3): 330-7.
34. van Kimmenade RR, Januzzi Jr. JL, Baggish AL, et al. Amino-Terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: rede fi ning the cardiorenal interaction?. J Am Coll Cardiol. 2006;48(8):1621-7.
35. Kim YK, Shin SJ, Ihm SH, et al. Association between N-Terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis. Int Urol Nephrol. 2010;42(2): 537-43.
36. Gutierrez OM, Tamez H, Bhan I, et al. N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem. 2008;54(8):1339-48.
37. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16):1733-9.
38. P fi sterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensi fi ed vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-92.
39. Lainchbury JG, Troughton RW, Strangman KM, et al. N-Terminal pro-B-Type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53-60.
40. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-Analysis of randomized controlled trials. Am Heart J. 2009;158(3):422-30.
41. McCullough PA, Haapio M, Mankad S, et al. Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25:1777-84.
42. Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail. 2008;14(7):539-46.
43. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-39.
44. Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291(5): F932-44.
45. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841-7.
46. Ronco C, Grammaticopoulos S, Rosner M, et al. Oliguria, creatinine and other biomarkers of acute kidney injury. Contrib Nephrol. 2010;164:118-27.